Research
Hormonal
Exenatide treatment significantly reduces dopamine transporter (DAT) availability in the striatum, caudate, and putamen in patients with Alcohol Use Disorder.
Exenatide changes the brain's dopamine transporter levels in key reward areas, which may help compensate for the dopamine deficits seen in chronic alcohol use. This is a biological mechanism, not a direct measure of drinking behavior.
GoodSupportsHIGH confidence
After 26 weeks of treatment, the analysis revealed a significant reduction of DAT in the striatum, caudate, and putamen in the exenatide group compared with placebo...
Why this rating
Substudy of the RCT with SPECT imaging, statistically significant.
Source
Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial
Mette Kruse Klausen et al. · JCI Insight · 2022
DOI 10.1172/jci.insight.159863
rct · n=127Cited 215×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Exenatide (2 mg once weekly) significantly reduces alcohol cue reactivity in the ventral striatum and septal area in patients with Alcohol Use Disorder, but does not significantly reduce heavy drinking days in the general AUD population.Good
- In obese patients with Alcohol Use Disorder (BMI > 30 kg/m2), exenatide significantly reduces heavy drinking days and total alcohol intake.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →